Kaneko 1969.

Methods	Allocation: implied randomisation Blindness: double‐blind ‐ tablets of the same external form Duration: 10 weeks (2 weeks placebo before the study started‐ 8 weeks for intervention) Design: parallel Setting: hospital Country: Japan
Participants	Diagnosis: schizophrenia N = 68 Age: 18‐60 years Sex: 52 M, 16 F History: including symptoms of severe excited state, stuporous state, hallucination, delusion or apathy. Symptoms were evaluated by a simplified scale for evaluation of psychogenic symptoms (for schizophrenia and for use by doctors) as 12 items, and the intensity of each item was assessed in five grades. Excluded: marked exacerbation or serious side effects, complete remission
Interventions	1. Clotiapine: maximum dose: 240 mg/d. N = 34 2. Chlorpromazine: maximum dose: 600 mg/d. N = 34
Outcomes	Mental state: average change score (PANSS positive and negative sub‐scale) Adverse effects: movement disorders, central nervous system, weight gain, thirst Leaving the study early Unable to use Mental state: improvement using Keio‐Gijuku University type, simplified scale, (no mean or SD)
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	High risk	No information was provided for randomisation
Allocation concealment (selection bias)	High risk	No information was provided for allocation concealment
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Quote: "Employed as the experimental method in the present study. was the double‐blind, controlled technique "
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	No information provided
Incomplete outcome data (attrition bias) All outcomes	Low risk	Missing data and attrition were addressed in the study.
Selective reporting (reporting bias)	Low risk	All pre‐specified outcomes were reported in the study.
Other bias	Unclear risk	Source of funding not reported